Elisabeth Hubert
Vorsitzender bei Fédération Nationale Etablissements Hospitalisation Domicile
Ursprung des Netzwerks ersten Grades von Elisabeth Hubert
Einheit | Art der Einheit | Industrie | |
---|---|---|---|
Institut National de la Santé & de la Recherche Médicale
Institut National de la Santé & de la Recherche Médicale Miscellaneous Commercial ServicesCommercial Services Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.
17
| Subsidiary | Miscellaneous Commercial Services | 17 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Elisabeth Hubert
Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
---|---|---|---|
OSE IMMUNOTHERAPEUTICS | Pharmaceuticals: Major | Chief Operating Officer Director/Board Member | |
Centre National de la Recherche Scientifique
Centre National de la Recherche Scientifique General GovernmentGovernment Centre National de la Recherche Scientifique provides scientific research services. The firm engages in the research capable of advancing knowledge and bringing social, cultural, and economic benefits for society. The company was founded in 1939 and is headquartered in Paris, France. | General Government | Corporate Officer/Principal Corporate Officer/Principal | |
Commission Nationale de Matériovigilance | Director/Board Member | ||
Société Européenne de Chirurgie Cardio-Vasculaire | Corporate Officer/Principal | ||
Association Internationale pour la Transplantation Cardiaque | Corporate Officer/Principal | ||
Société Française de Chirurgie Thoracique & Cardio-Vasculaire | Corporate Officer/Principal | ||
Hopital Guillaume et René Laënnec | Corporate Officer/Principal | ||
AstraZeneca SAS
AstraZeneca SAS Pharmaceuticals: MajorHealth Technology AstraZeneca SAS researches, develops, produces, and commercializes pharmaceutical products. It offers solutions in different domains such as cardio-vascular, metabolism, oncology, respiratory, and inflammatory diseases. The company was founded on April 21, 1955 and is headquartered in Courbevoie, France. | Pharmaceuticals: Major | Chief Executive Officer | |
BLUEBIRD BIO, INC. | Biotechnology | Founder | |
ASTRA France SA
ASTRA France SA Miscellaneous Commercial ServicesCommercial Services Part of SES SA, ASTRA France SA is a French company that provides business and management consultancy services. The company is based in Paris, France. | Miscellaneous Commercial Services | Chief Executive Officer | |
Société Française de Cardiologie | Corporate Officer/Principal | ||
Fondation Coeur Et Recherche
Fondation Coeur Et Recherche Miscellaneous Commercial ServicesCommercial Services Fondation Coeur Et Recherche operates a voluntary membership organization. The private company is based in Paris, France. | Miscellaneous Commercial Services | Director/Board Member | |
Agence Française de Sécurité Sanitaire des Produits de Santé | Director/Board Member | ||
La Référence Formation des Industries de Santé | Director/Board Member | ||
Eratos Santé SARL | Corporate Officer/Principal | ||
Fédération Françaises des Industries de Santé | Corporate Officer/Principal | ||
French Cardiology Association | Corporate Officer/Principal | ||
Institut De Formation Des Industries De Santé
Institut De Formation Des Industries De Santé Miscellaneous Commercial ServicesCommercial Services Institut De Formation Des Industries De Santé is a private company based in Paris, France. The French company provides training services to the pharmaceutical and health sectors. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
Université Catholique de Louvain | College/University | Doctorate Degree | |
Kidney Disease Improving Global Outcomes | Corporate Officer/Principal | ||
Global Antibiotic Research & Development Partnership
Global Antibiotic Research & Development Partnership BiotechnologyHealth Technology Global Antibiotic Research & Development Partnership is a Swiss company that is working to combat antibiotic resistance. The non-profit company is based in Geneva, Switzerland. Antibiotic resistance occurs when bacteria no longer respond to treatment, and millions of people suffer from this every year. The company is developing a new initiative called SECURE, which aims to provide access to essential antibiotics and prepare for and respond to pandemics. | Biotechnology | Director/Board Member | |
Egenix, Inc.
Egenix, Inc. BiotechnologyHealth Technology Part of Denan, Inc., Egenix, Inc. engages in cancer therapeutics research and development. The company is based in Millbrook, NY. Egenix was acquired by Denan, Inc. on June 10, 2015 for $0.82 million. | Biotechnology | Director/Board Member | |
Université PSL | College/University | Director/Board Member | |
Institut Pasteur
Institut Pasteur Investment Trusts/Mutual FundsMiscellaneous The Institut Pasteur is a private non-profit foundation which contributes to the prevention and treatment of disease, through research, education, and public health activities. The firm was founded in 1887, and is based in Paris. | Investment Trusts/Mutual Funds | Director/Board Member | |
Inserm-Transfert SA
Inserm-Transfert SA Miscellaneous Commercial ServicesCommercial Services Inserm-Transfert SA engages in the managements of economic and societal value creation and the transfer of knowledge. It operates in the human health innovation sector. The company was founded in 2000 and is headquartered in Paris, France. | Miscellaneous Commercial Services | Chairman | |
bioMERIEUX Benelux SANV
bioMERIEUX Benelux SANV Medical SpecialtiesHealth Technology bioMERIEUX Benelux SANV is specialized in the field of in vitro diagnostics for medical and industrial applications. The group designs, develops, manufactures and markets systems used in clinical applications (diagnosis of infectious diseases based on the analysis of biological samples) and industrial applications (the analysis of industrial or environmental samples to determine its microbiological quality). The company was founded in 1979 and is headquartered in Bruxelles, Belgium | Medical Specialties | Director/Board Member | |
Fondation Mérieux | Investment Trusts/Mutual Funds | Director/Board Member | |
Université de Montpellier | College/University | Doctorate Degree | |
Human Vaccine Project | Director/Board Member | ||
Xenothera SAS
Xenothera SAS BiotechnologyHealth Technology Xenothera SAS is a biotechnologies company. It creates therapeutic modes in numerous domains from immunomodulation to infectious diseases. The company was founded on June 30, 2014 and is headquartered in | Biotechnology | Chief Operating Officer | |
World Health Organization
World Health Organization SupranationalGovernment World Health Organization provides voluntary medical services. It is the United Nations' agency for health. WHO is governed by countries that approve funding, programs and policies related to public health and health related social issues through the world health assembly. Some of the health and social issues which the organization addresses are communicable & non-communicable diseases, community & family health, hunger, health technology, mental health, pharmaceuticals and sustainable development. Founded on April 7, 1948, the organization is headquartered in Geneva, Switzerland. | Supranational | Corporate Officer/Principal | |
BIOMÉRIEUX | Medical Specialties | Director/Board Member | |
Medicines Patent Pool Foundation | Chairman | ||
Drugs for Neglected Diseases initiative
Drugs for Neglected Diseases initiative BiotechnologyHealth Technology Drugs for Neglected Diseases initiative provides drug research and development services. It specializes in analyzing the causes of and in developing medicine and treatments for neglected diseases. It specializes in the study of neglected tropical diseases, such as sleeping sickness (Human African Trypanosomiasis), Leishmaniasis, Chagas, malaria, pediatric HIV, and filarial diseases. It develops a research and development portfolio that includes projects from discovery through to post-registration phases. Its focus areas encompass regional disease-specific platform development, technology transfer, and public responsibility and awareness advocacies. The organization was founded in July 2003 and is headquartered in Geneva, Switzerland. | Biotechnology | Chairman | |
BioMAdvanced Diagnostics SAS
BioMAdvanced Diagnostics SAS Medical SpecialtiesHealth Technology BioMAdvanced Diagnostics SAS produces molecular diagnostic and biomarker tests related to the immune system. The company is based in Nantes, France. The French company was founded by Nicolas Bouler, Frédéric Pette, Sophie Brouard, Jean-Michel Bouler. Frédéric Pette has been the CEO since incorporation. | Medical Specialties | Founder | |
Société Française D Immunologie | Director/Board Member | ||
Fondation Centaure | Director/Board Member | ||
Harvard Medical School | College/University | Graduate Degree | |
CEGEDIM | Packaged Software | Director/Board Member | |
Eberhard Karls Universität Tübingen | College/University | Doctorate Degree | |
Hopital Necker-Enfants Malades | Corporate Officer/Principal | ||
Paris Institute of Technology | College/University | Undergraduate Degree | |
Cellerix SA
Cellerix SA Pharmaceuticals: GenericHealth Technology Founded in 2004, Cellerix is a biopharmaceutical company that develops innovative treatments based on cell therapy. Cellerix was founded within the Genetrix Group, group of biotechnology companies specialising in biomedicine. The Genetrix Group began its activities in 2001 at the National Centre for Biotechnology (CNB), which belongs to the Spanish Research Council (CSIC). One of the main objectives of Genetrix is to convert basic research results into therapeutic realities. Cellerix is leading the development of a new generation of medicines using expanded adult stem cells from adipose tissue (eASCs). Development is at a clinically advanced stage and the results from clinical trials in Phase I and II have been very promising. Obtaining these eASCs has big advantages because the process makes use of tissue that is almost always discarded from surgical procedures such as liposuction. eASCs have the capacity to activate physiological repair mechanisms through interaction with affected tissue. This technology represents a revolution in the treatment of some diseases that cannot satisfactorily be cured at present. Cellerix is working actively to adapt this new therapeutic strategy to treat autoimmune diseases such as inflammatory bowel disease. The main goal of the company is to market new tools for treating these diseases, which have a considerable negative impact of the quality of life of the sufferers. Cellerix also researches and develops medicines in other areas such as the development of skin equivalents, which are initially intended for the treatment of hereditary diseases such as epidermolysis bullosa. | Pharmaceuticals: Generic | Director/Board Member | |
BioVex, Inc.
BioVex, Inc. Pharmaceuticals: MajorHealth Technology BioVex, Inc. develops vaccines for the treatment of cancer and the prevention of chronic infectious diseases. Its products include OncoVEX oncolytic and ImmunoVEX technology. The company was founded in 1999 by Dr. Robert Coffin and is headquartered in Woburn, MA. | Pharmaceuticals: Major | Director/Board Member | |
École Centrale Paris | College/University | Undergraduate Degree | |
Ventech SA
Ventech SA Investment ManagersFinance Ventech SA is part of the venture capital arm and a wholly-owned subsidiary of Natixis Private Equity (NPE), which in turn is a subsidiary of Paris-based Natixis SA (XP: KN). Ventech was established in 1998 and is located in Paris. The firm specializes in technology venture capital investing. Ventech manages venture capital funds for a clientele of European institutional investors, with NPE as their sponsor. The firm relies on international strategic alliances with seeding funds and venture capital firms in Germany, Switzerland, Israel, Japan and the US. | Investment Managers | Private Equity Investor |
Statistik
International
Frankreich | 36 |
Vereinigte Staaten | 7 |
Schweiz | 5 |
Belgien | 4 |
Deutschland | 2 |
Sektoral
Health Technology | 15 |
Consumer Services | 8 |
Commercial Services | 6 |
Finance | 3 |
Government | 3 |
Operativ
Director/Board Member | 45 |
Corporate Officer/Principal | 27 |
Founder | 12 |
Doctorate Degree | 6 |
Chairman | 6 |
Am stärksten vernetzte Beziehungen
- Börse
- Insiders
- Elisabeth Hubert
- Unternehmensverbindungen